Aldosterone synthase inhibitors in CKD (and EASi-KIDNEY’s outline design)

The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial

Access the article here

Speaker
Parminder Judge, United Kingdom

Panellists
Pantelis Sarafidis, Greece
Christoph Wanner, Germany

Moderator
Jennifer Lees, United Kingdom

Thursday, February 27, 2025, 5:00 PM (CET)